89bio, Inc. (ETNB)
NASDAQ: ETNB · Real-Time Price · USD
8.01
+0.07 (0.88%)
Dec 26, 2024, 12:16 PM EST - Market open
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
The company was incorporated in 2018 and is headquartered in San Francisco, California.
89bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Nov 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Rohan Palekar |
Contact Details
Address: 142 Sansome Street, Second Floor San Francisco, California 94104 United States | |
| Phone | 415 432 9270 |
| Website | 89bio.com |
Stock Details
| Ticker Symbol | ETNB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001785173 |
| CUSIP Number | 282559103 |
| ISIN Number | US2825591033 |
| Employer ID | 83-1114349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rohan Palekar | Chief Executive Officer and Director |
| Quoc Le-Nguyen | Chief Technical Officer |
| Dr. Harry Mansbach M.D. | Chief Medical Officer |
| Ryan Stephen Martins | Chief Financial Officer |
| Francis W. Sarena | Chief Operating Officer |
| Shiva K. Natarajan CPA | Senior Vice President of Finance and Principal Accounting Officer |
| Annie J. Chang M.B.A. | Vice President of Investor Relations and Corporate Communications |
| Amanda Kurihara | Vice President of People and Culture |
| Melissa Abel | Senior Vice President of Commercial Strategy |
| Paul Shin | Senior Vice President of Research & Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | SCHEDULE 13G | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 424B5 | Filing |
| Nov 12, 2024 | 424B5 | Filing |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |